Editas Medicine, Inc.

NASDAQ:EDIT

Biotechnology

Healthcare
$1.77 +2.65%

+$0.07 today

Market cap
$273.18M
Beta
2.10
P/E (TTM)
-2.4
EPS (TTM)
-$1.11
52W Low $1.66High $4.54

Volume 1.99M

Average 2.06M

EDIT Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Editas Medicine, Inc.NASDAQ: EDIT

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 97.88M shares rose 17.8% year over year, ahead of the +9.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 10.3% from the prior quarter. Over 3 fiscal years it compounded at +8.9% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +17.8% holds above the trailing-twelve-month pace of +9.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
97.88M+10.3% QoQ
Last fiscal yearDec 2025
88.75M+7.8% YoY
LTMMar 2026
90.28M+9.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.8%——
1 year+7.8%——
3-year CAGR+8.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
88.75M USD
Year-over-year change
+7.8%
4-year CAGR
+7.0%

Weighted Avg Shares (Diluted) vs competitors

How EDIT compares with its peers on the latest reported figures

  • EDIT's LTM Mar 2026 weighted avg shares (diluted) of 90.28M shares is the 7th highest of the 9 companies compared; the peer median is 99.29M shares.
  • Its year-over-year change of +9.3% is the 7th highest of 9, against a peer median of +14.9%.
  • Over three fiscal years its annual growth of +8.9% compares with a peer median of +15.3%.
EDIT Competitors Peer median
Weighted Avg Shares (Diluted) for EDIT and competitors
Company Period LTM YoY 3-year CAGR
PRMEPrime Medicine, Inc.LTM Mar 2026153.89M +26.0%+15.2%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026111.46M +12.7%+17.7%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026110.2M +9.3%+12.1%
BEAMBeam Therapeutics Inc.LTM Jun 2026103.77M +17.0%+12.2%
CRSPCRISPR Therapeutics AGLTM Sep 202694.81M +8.4%+5.0%
CRBUCaribou Biosciences, Inc.LTM Mar 202694.18M +3.6%+15.4%
EDITEditas Medicine, Inc.LTM Mar 202690.28M +9.3%+8.9%
BNTCBenitec Biopharma Inc.LTM Mar 202643.27M +112.6%+166.1%
DTILPrecision BioSciences, Inc.LTM Mar 202612.13M +60.9%+63.6%
SCTXScribe Therapeutics Inc.—— ——
Peer median (excluding EDIT) 99.29M+14.9%+15.3%

Competitors are the stored peer set for EDIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue25.54M19.71M78.12M32.31M40.52M
Cost of Revenue5.05M6.34M6.06M199.25M0
Gross Profit20.49M13.38M72.06M(166.93M)40.52M
Gross Margin80.2%67.9%92.2%-516.6%100.0%
Research & Development142.51M174.96M177.65M199.25M89.95M
Selling, General & Admin76.18M70.7M69.65M71.99M49.9M
Operating Expenses213.64M239.33M241.24M84.22M139.86M
Depreciation & Amortization5.05M6.34M6.06M5.81M5.28M
EBITDA(187.45M)(214.1M)(147.16M)(233.11M)(148.61M)
EBITDA Margin-733.8%-1086.1%-188.4%-721.4%-366.8%
Operating Income(193.15M)(225.95M)(169.18M)(251.15M)(99.34M)
Operating Margin-756.1%-1146.3%-216.6%-777.2%-245.2%
Interest Income607K5.52M17.57M14.06M8.31M
Interest Expense00006.17M
Other Income / Expenses644K5.52M15.96M14.06M(60.72M)
Income Before Tax(192.5M)(220.43M)(153.22M)(237.09M)(160.06M)
Pre-Tax Margin-753.6%-1118.3%-196.1%-733.7%-395.0%
Income Tax Expense00000
Net Income(192.5M)(220.43M)(153.22M)(237.09M)(160.06M)
Net Margin-753.6%-1118.3%-196.1%-733.7%-395.0%
EPS (Basic)(2.85)(3.21)(2.02)(2.88)(1.80)
EPS (Diluted)(2.85)(3.21)(2.02)(2.88)(1.80)
Weighted Avg Shares67.62M68.66M75.97M82.34M88.75M
Weighted Avg Shares (Diluted)67.62M68.66M75.97M82.34M88.75M

Editas Medicine, Inc.

NASDAQ:EDIT

Intrinsic Alpha fair value

Locked

Current Price

$1.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.